Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Vol.09, 2026.3.17
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Editor's Note: In 2026, the Qiming Weekly has been upgraded and refreshed, with regular weekly updates featuring only ten major developments from Qiming Venture Partners' portfolio companies, covering funding progress and breakthroughs.
In the wave of technology and innovation, every step entrepreneurs take deserves to be recorded. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and we look forward to sharing these milestone moments with you.
Funding News
01/
Jieti Medical Completes 500 Million Yuan Strategic Financing Round
Recently, Jieti Medical announced the completion of a 500 million yuan strategic financing round, with continued investment from Qiming Venture Partners. Bolstered by this capital injection, Jieti Medical has demonstrated strong momentum in both technical breakthroughs and clinical advancement. Following three successful brain-computer interface (BCI) clinical trials last year, the company's clinical progress has continued to accelerate: in early 2026, leveraging its self-developed surgical robot, Jieti Medical completed the clinical implantation of its WRS02 — a 256-channel wireless high-throughput invasive BCI system intended for registration — and achieved effective validation of brain-controlled interactive functions. This represents not only a technical leap for Jieti Medical but also China's first 256-channel invasive BCI clinical trial, marking a revolutionary step forward for the country in high-performance invasive BCI. The WRS02 is also currently the only invasive BCI product approved for the National Medical Products Administration's "Green Channel" for innovative medical devices.
Building on this success, Jieti Medical is now preparing for more ambitious clinical expansion. The company plans to launch large-scale multi-center registration clinical trials in mid-2026, with the goal of enrolling and implanting approximately 40 patients within the year. By the end of 2026, Jieti Medical's total number of clinical implantations could approach or even surpass Neuralink's current clinical trial total (approximately 21 cases), signaling that Chinese BCI companies are sprinting toward global leadership in commercialization and clinical deployment.
Jieti Medical founder Xue Li stated: "Brain-computer interfaces are not just a cutting-edge medical technology — they represent the ultimate convergence of life sciences and information technology. The deep expertise that major tech companies have accumulated in multimodal large models, computing infrastructure, intelligent hardware, and ecosystem deployment can be deeply integrated with Jieti Medical's globally leading BCI hardware capabilities and clinical translation experience. This powerful collaboration will jointly build a next-generation intelligent BCI system and a rich ecosystem of frontier applications. This is not only support for medical innovation, but also a forward-looking investment in the underlying capabilities of next-generation human-machine interaction."
02/
Tianwu Technology Completes Over 200 Million Yuan Series A+ Round
Recently, Tianwu Technology, an AI-driven full-stack protein R&D platform, completed an A+ round of over 200 million yuan, with continued investment from Qiming Venture Partners.
Tianwu Technology is an AI-driven full-stack protein R&D platform company. By building a proprietary, large-scale protein sequence dataset and tag library — one that no one else has — the company has developed a general-purpose protein design foundation model, enabling precise functional protein design directly tailored to industry needs.
With its self-developed protein foundation model as the core engine, Tianwu Technology has developed research intelligent agents and automated experimental devices, creating a full-stack AI protein R&D platform spanning market, literature, and patent research; molecular design; small-scale validation; pilot process optimization; and production scale-up. By bringing AI fully into industrial application scenarios, the platform pushes beyond the cognitive boundaries of existing human expertise to develop various protein-based products — such as innovative drugs, health and wellness products, agricultural solutions, functional foods, and bio-based materials — faster and better.
Major Partnerships
01/
WeRide Robotaxi Officially Integrated into Tencent Mobility Services Mini Program
Qiming Venture Partners portfolio company WeRide (NASDAQ: WRD, 0800.HK), a global leader in autonomous driving technology, announced a deepened strategic partnership with Tencent Cloud. Effective immediately, WeRide Robotaxi is officially available through the "Tencent Mobility Services" mini program, allowing users to call and pay for Robotaxi rides within WeChat without switching apps.
Through the "Tencent Mobility Services" mini program — a high-frequency WeChat service entry point — WeRide Robotaxi will reach massive numbers of WeChat users and integrate into daily travel scenarios. As user reach and usage frequency continue to grow, WeChat's vast ecosystem traffic will translate into a stable order pipeline for WeRide, accelerating the company's Robotaxi commercialization at scale and moving quickly toward the important milestone of per-vehicle profitability. In the near future, WeRide's Robotaxi service will also launch on Tencent Maps, further expanding autonomous mobility channel options.
Currently, users in Guangzhou can be the first to experience WeRide Robotaxi through "Tencent Mobility Services," with plans to gradually open access to additional cities. Users simply navigate to "Me" → "Services" → "Mobility Services" within WeChat to enter the Tencent Mobility Services ride-hailing interface, enter their origin and destination, and if a WeRide Robotaxi stop is available nearby, they can select "Autonomous Driving — WeRide Mobility" to call a ride with one tap. First-time users will enjoy exclusive ride discounts for a premium experience in WeRide's spacious and comfortable five-seat GXR vehicle.
02/
Hesai Technology LiDAR Secures Multi-Vehicle Design Win with BAIC Group
Recently, global LiDAR leader Hesai Technology (NASDAQ: HSAI, 02525.HK) announced that its ATX Refresh has officially secured multi-vehicle design wins with BAIC Group, with mass production and delivery expected to begin as early as the second half of 2026. With industry-leading safety technology, Hesai Technology is becoming the common choice of mainstream automakers, injecting core perception capabilities into the intelligent upgrade of the automotive industry.
Hesai Technology's compact high-performance long-range LiDAR ATX combines small form factor with extreme performance. Since launching mass production in Q1 2025, it has rapidly become a standard safety component for best-selling mass-production models, with cumulative deliveries exceeding 1 million units. The ATX Refresh, launched in November, pushes both performance ceilings and safety floors to the extreme. It has already secured orders for over 4 million units from multiple global top-tier OEMs, with mass production and delivery expected to begin in April 2026. To date, Hesai Technology has secured mass production design wins for over 160 vehicle models across 40 automotive brands, covering all of China's top ten automakers by sales volume, and has won full-vehicle-series design wins for 2026 from its top two ADAS customers.
03/
Wondershare Technology and Shengshu Technology Launch China's First One-Stop AI Comic Drama Creation Platform
Recently, Wondershare Technology Group Co., Ltd (30064.SZ) and Qiming Venture Partners portfolio company Shengshu Technology jointly announced the official launch of "Wondershare Drama Factory" (reelmate.cn) — China's first benchmark product combining "full-chain premium comic drama tools + deep co-creation with comic drama foundation models." The two parties are reconstructing AI comic drama industrialization standards through "foundation model + tools + scenarios," ushering in an intelligent new era where "everyone can be a comic drama creator."
The Vidu Q3 Model AI Comic Drama Solution is purpose-built for the comic drama industry from the ground up. It directly addresses core pain points in comic drama creation with four dedicated solutions: precise control of non-humanoid characters, coherent multi-shot generation, intelligent prompt optimization, and voice-over lip sync. From underlying algorithms to functional design, this model solution is fully oriented around comic drama content production needs, achieving multi-dimensional stable control over subjects, voice tones, environments, and props. It supports multiple professional cinematic camera angles including shot-reverse-shot, over-the-shoulder, high/low angles, and POV; features a built-in prompt optimization bot that significantly lowers the barrier to entry; and introduces a spatial structure control mechanism that effectively solves continuity challenges in shot production, providing a solid technical foundation for industrialized comic drama production.
04/
Renji Hospital Shanghai and Cornerstone Robotics Establish Integrated Training and Certification Center for Surgical Robots
Recently, the "Clinical Application Standardization Training Base for AI-Assisted Treatment Technologies" at Renji Hospital, Shanghai Jiao Tong University School of Medicine, was officially unveiled. The Surgical Robot International Training Center, jointly established by Qiming Venture Partners portfolio company Cornerstone Robotics and Renji Hospital, received its accreditation at the base. Marking a new starting point, the training center not only successfully launched its first training program but has also initiated regular operations for the "AI-Assisted Treatment Technology Basic Skills Assessment," representing a solid step forward for both parties in promoting the普及 of surgical robot-assisted surgery and standardized talent cultivation. This strategic partnership aims to deeply integrate medical and engineering advantages, building a comprehensive hub integrating clinical training, technical exchange, and certification — continuously empowering the overall advancement of regional minimally invasive surgical diagnosis and treatment capabilities.
The Surgical Robot International Training Center jointly established by Cornerstone Robotics and Renji Hospital is an important component of this base. As the only domestic multi-arm surgical robot brand at the training center, Cornerstone Robotics and Renji Hospital's strengths are highly complementary. Cornerstone Robotics has long been dedicated to the independent R&D and clinical promotion of laparoscopic surgical robots. Relying on fully self-owned intellectual property core technology, the company has established mature education and training mechanisms with multiple key medical institutions at home and abroad, accumulating extensive experience in robotic surgery training system design and implementation, and continuously promoting the deep integration of frontier technology with complex clinical scenarios. This collaboration to build the training center represents the organic integration of Renji Hospital's top-tier clinical resources with Cornerstone Robotics' systematic technical training capabilities. Through standardized curriculum delivery and high-fidelity clinical simulation exercises, it cultivates composite surgical talent with solid theoretical literacy and precise practical skills for the industry, jointly advancing the intelligent surgery talent cultivation system to new heights.
Product Launches
01/
Zhipu AI Launches GLM-5-Turbo Lobster-Enhanced Foundation Model
Recently, Qiming Venture Partners portfolio company Zhipu AI (02513.HK) officially launched AutoClaw (Chinese name: Aolong / "Australian Lobster"), China's first truly one-click-installable local version of OpenClaw, pre-loaded with 50+ popular Skills and supporting one-click integration with Lark and other instant messaging tools. A single download transforms users' computers into 24/7 dedicated productivity assistants. Agent capabilities are growing stronger with each model iteration, but extremely high barriers to entry have kept 99% of people on the outside. Zhipu AI hopes that AutoClaw's launch will further advance AI democratization, truly realizing the vision of "everyone raising lobsters."
At the same time, Zhipu AI officially launched the "Lobster National Deployment Plan," offering one-click-install computer version Lobster "AutoClaw Aolong" installation services to interested local governments, enterprises, and universities nationwide. The company is also recruiting tech enthusiasts and KOLs across the country to join the "Lobster Evangelist" program, helping more people get started with Lobster, with Zhipu AI providing relevant AI model and OpenClaw training.
Additionally, Zhipu AI formally introduced the GLM-5-Turbo foundation model, specifically optimized for OpenClaw Lobster scenarios. GLM-5-Turbo receives specialized optimization from the training stage for Lobster tasks' core requirements, enhancing core capabilities such as tool calling, instruction following, scheduled and persistent tasks, and long-chain execution. It achieved first place among domestic models on the self-developed ZClawBench benchmark test, and received high praise from multiple major internet companies in internal Lobster scenario testing. Zhipu AI also launched the Claw Lobster package and the Claw Security Management System for enterprise-level scenarios.
02/
StepFun Releases Cloud-Based AI Assistant StepClaw
Recently, Qiming Venture Partners portfolio company StepFun announced the launch of StepClaw ("Jieyue Longxia"), a cloud-based AI assistant built on OpenClaw, supporting one-click deployment and invocation within the StepFun AI app, with 24/7 availability. At the same time, users no longer need to worry about being unable to get or afford a "lobster." StepClaw is opening 50,000 free one-click deployment and experience slots, free for a limited one-month period.
StepClaw's core advantage lies in its cloud architecture. Its cloud deployment features dual-core CPU, 4GB RAM, and 40GB storage. It smoothly executes complex tasks without lag; with 40GB of storage space, it possesses long-term memory capabilities, growing more attuned to user habits over time; it remains online 24/7, continuing to run in the cloud even when the screen is locked or the device is powered off, and proactively notifies users of new developments. StepClaw comes standard with StepFun's open-source Step 3.5 Flash model. Since its full open-source release in early March, this model rapidly topped the OpenClaw monthly model call volume rankings and has held the global #1 position for multiple consecutive days.
03/
Biren Technology Jointly Releases LightSphere 128 Commercial Edition
Recently, at the opening ceremony of AWE (Appliance & Electronics World Expo), Biren Technology (06082.HK) jointly released the LightSphere 128 commercial edition with Shanghai Yidian, Lightelligence, and ZTE. This significant release marks the achievement of this China-original optical interconnection and optical switching supernode solution — going from proof-of-concept to commercial deployment in just over six months. Currently, LightSphere has achieved deployment at the scale of thousands of cards.
Since its initial release at the 2025 World Artificial Intelligence Conference, LightSphere has undergone over six months of joint攻关, successfully achieving the 128-card commercial edition. As China's first optical interconnection and optical switching GPU supernode solution, this original technical achievement born and grown in Shanghai takes Lightelligence's globally pioneering silicon photonics OCS optical switching chip as its core,搭载 Biren Technology's self-developed architecture large-compute general-purpose GPU liquid-cooled module Bili™ 166L, and integrates ZTE's high-performance AI servers and self-developed software platform, constructing a fully self-contained new paradigm for intelligent computing clusters.
Technology Strength
Hongji Medical Debuts at European Association of Urology Annual Congress
Recently, the European Association of Urology Annual Congress (EAU26) opened in London. Qiming Venture Partners portfolio company Hongji Medical made its international debut with multiple new urology products, bringing more controllable, more precise, multi-product-line systematic solutions to the global stage.
EAU26 coincided with the second anniversary of the HU30M 6.3Fr single-use digital flexible ureteroscope launch. As a revolutionary product with an ultra-fine caliber, the 6.3Fr flexible ureteroscope has gained widespread recognition in global multi-center clinical applications — a terminal user group represented by nine KOLs from different countries gave the 6.3Fr flexible ureteroscope high praise, fully affirming its comprehensive performance in miniaturization breakthroughs, temperature and pressure control capabilities, and maneuverability.
Progress in urology is increasingly following two clear paths: finer endoscopes, more controllable systems. Around this trend, Hongji Medical has built an intraoperative closed-loop system covering temperature and pressure-controlled endoscopes, pump systems, supporting consumables, and platform equipment, continuously strengthening intrarenal pressure management and temperature control capabilities, responding to the development direction of miniaturization and precision.
P R E V I O U S I S S U E S
Qiming Venture Partners was founded in 2006. Currently, the firm manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, Qiming has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ: HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ: WRD, 0800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu AI (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Insilico Medicine (03696.HK), Arbutus Biopharma, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, and others.